The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)

NACompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

December 3, 2019

Study Completion Date

May 6, 2020

Conditions
Hemorrhage
Interventions
DEVICE

SURGICEL Powder

Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.

DEVICE

SURGICEL Original

Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.

Trial Locations (6)

Unknown

Zhejiang Provincial People's Hospital, Hangzhou

Jiangsu Province Hospital, Nanjing

Nanjing Drum Tower Hospital - Nanjing University Medical School, Nanjing

Ruijin Hospital - Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai Xinhua Hospital, Shanghai

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

Ethicon, LLC

INDUSTRY

NCT03783039 - The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study) | Biotech Hunter | Biotech Hunter